Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: Comparison of skin from patients with end-stage renal disease and skin from healthy subjects

Investigative Radiology

Volumn 45, Issue 11, 2010, Pages 733-739

  Dasilva, Marissa ^a   Deming, Monica O'Brien ^a   Fligiel, Suzanne E G ^a   Dame, Michael K ^a   Johnson, Kent J ^a   Swartz, Richard D ^a   Varani, James ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

gadolinium based contrast agent (GBCA); hyaluronan; matrix metalloproteinase I (MMP 1); nephrogenic systemic fibrosis (NSF); omniscan; tissue inhibitor of metalloproteinases 1 (TIMP 1); type I procollagen

Indexed keywords

GADODIAMIDE; GADOLINIUM; HYALURONIC ACID; INTERSTITIAL COLLAGENASE; IRON; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; RECOMBINANT ERYTHROPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ANEMIA; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME SYNTHESIS; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY FAILURE; MALE; MONOLAYER CULTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN CULTURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN; SKIN BIOPSY; SKIN FIBROBLAST;

EID: 77958481110     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181e9436b     Document Type: Article

References (62)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563-572.
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
4. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
5. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238-249.
6. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263.
7. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
8. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
9. Rydahl C, Thomsen HS, Marckmann R. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
10. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. Am J Radiol. 2008;190:736-741.
11. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199.
12. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
13. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentate dimeglumine. Invest Radiol. 2009;44:135-139.
14. McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol. 2002;41:364-367.
15. Neudecker BA, Stern R, Mark LA, et al. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol. 2005;32:612-615.
16. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant. 2002;17:33-38.
17. Chatziantoniou C, Boffa JJ, Tharaux PL, et al. Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol. 2004;85:1-11.
18. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65:1357-1365. (Pubitemid 38406974)
19. Cai G, Zhang X, Hong Q, et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Neph-rol Dial Transplant. 2008;23:1861-1875.
20. Stahl RAK, Wolf G, Thaiss F. The possible role of chemotactic cytokines in renal disease. Clin Invest. 1994;72:711-712.
21. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
22. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
23. Perone P, Weber S, DaSilva M, et al. Collagenase activity is suppressed by elevated tissue inhibitor of metalloproteinase-1 (TIMP-1) in human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol. 2010;45: 42-48.
24. Varani J, Perone P, Griffiths CE, et al. All-trans retinoic acid (RA) stimulates events in organ-cultured human skin that underlie repair. Adult skin from sun-protected and sun-exposed sites responds in an identical manner to RA while neonatal foreskin responds differently. J Clin Invest. 1994;94:1747-1756.
25. Varani J, Fay K, Perone P. MDI 301, a non-irritating retinoid, induces changes in human skin that underlie repair. Arch Dermatol Res. 2007;298: 439-448.
26. Reale E, Luciano L, Spitznas M. Histochemical demonstration of hyaluronic acid molecules by alcian blue. Histochem J. 1986;18:306-316.
27. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214:584-593.
28. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodi-alysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5: 491-502.
29. Lin SP, Brown JJ. MR contrast agents: physical and pharmacological basics. J Magn Reson Imaging. 2007;25:884-899.
30. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66:175-179.
31. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.
32. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007; 56:21-26.
33. Boyd Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30.
34. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol. 2008;190:1060-1068.
35. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
36. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 2009;60:1508-1518.
37. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis\-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodia-mide. Exp Toxicol Pathol. 2009;61:537-542.
38. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
39. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. JMagn Reson Imaging. 2008;27:955-962.
40. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
41. Grant D, Johnsen H, Juelsrud A, et al. Effect of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156-169.
42. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004;150:1050-1052.
43. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870.
44. Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial. 2008;21:150-154.
45. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008;248:77-88.
46. Brambilla S, Valaperta S, Graziani G, et al. Gadolinium and lanthanum: a iatrogenic transmettaltion? Clin Biochem. 2008;41:1029-1033.
47. Idee JM, Port M, Dencausse A, et al. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am. 2009;47:855-869.
48. Hope TA, High WA, LeBoit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology. 2009;253:390-398.
49. Klein EA, Campbell LE, Kothapalli D, et al. Joint requirement for Rac and ERK activities underlies the mid-G1 phase induction of cyclin D1 and S phase entry in both epithelial and mesenchymal cells. J Biol Chem. 2008; 283:30911-30918.
50. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine. 2000;12:1469-1479.
51. Stambolic V, Woodgett JR. Functional distinctions of protein kinase B/Akt isoforms defined by their influence on migration. Trends Cell Biol. 2006;16: 461-466.
52. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/ NF-kappaB pathway. J Leukoc Biol. 2005;78:259-265.
53. Oh JH, Kim A, Park JM, et al. Ultraviolet B-induced matrix metalloprotein-ase-1 and-3 secretions are mediated via PTEN/Akt pathway in human dermal fibroblasts. J Cell Physiol. 2006;209:775-785.
54. Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379:335-339.
55. Tong L, Smyth D, Kerr C, et al. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cell Signal. 2004;16:1123-1132.
56. Stuhlmeier KM, Pollaschek C. Differential effect of transforming growth factor beta (TGF-beta) on the genes encoding hyaluronan synthase and utilization of the p38 MAPK pathway in TGF-beta-induced hyaluronan synthase 1 activation. J Biol Chem. 2004;279:8753-8760.
57. Dervisoglu E, Kir HM, Kalender B, et al. Depressive symptoms and proin-flammatory cytokine levels in chronic renal failure patients. Nephron Clin Pract. 2008;108:c272-c277.
58. Riancho JA, Zarrabeitia MT, de Francisco AL, et al. Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron. 1993; 65:364-368.
59. Patterson JW. The perforating disorders. J Am Acad Dermatol. 1984;10:561-581.
60. Randle HW. Keratotic papules of chronic renal failure: the process of transepithelial elimination. Arch Dermatol. 1983;119:874-875.
61. Hood AF, Hardegen GL, Zarate AR, et al. Kyrle's disease in patients with chronic renal failure. Arch Dermatol. 1982;118:85-88.
62. Nickoloff BJ, Noodleman FR, Abel EA. Perforating pseudoxanthoma elasti-cum associated with chronic renal failure and hemodialysis. Arch Dermatol. 1985;121:1321-1322.